A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

This article presents information related to patients with relapsed Hodgkin's disease. The objective of the radomized trial of chemotherapy is to compare efficacy and toxicity of a sequential HDCT and a standard HDCT in patients with histologically confirmed relapsed Hodgkin's disease. Primary endpoint of the study is freedom from treatment failure in both treatment arms. Secondary endpoints are complete remission, complete remission unconfirmed rates 3 months after end of protocol, relapse-free survival overall survival, frequency of severe toxicities and secondary neoplasia.